Recent Company News

• 03:38 PM ET Oct 11, 2026
  

  BridgeBio Pharma reports Phase 3 ATTRibute-CM sub-analyses of acoramidis in ATTR-CM presented at HFSA ($65.35, 0.00)

• 02:31 AM ET Oct 08, 2026
  

  US FDA accepts Bayer's supplemental NDA for KERENDIA (finerenone) to treat adults with chronic kidney disease (CKD) without diabetes (€43.97, 0.00)

• 09:23 AM ET Oct 06, 2026
  

  Mint Pharmaceuticals (private) expands distribution agreement in Canada with Bayer (€44.72, +0.76)

• 11:18 AM ET Oct 05, 2026
  

  Zydus Lifesciences announces launch of Riociguat Tablets in US (INR 1138.50, 0.00)

• 02:46 AM ET Oct 05, 2026
  

  StreetAccount Summary - European pre-market trading update

• 03:15 PM ET Oct 02, 2026
  

  Bayer AG to invest $2.2B in new manufacturing site in New Albany, Ohio (€44.94, 0.00)

• 07:35 AM ET Sep 30, 2026
  

  Cytokinetics launches ASPEN-HCM: a real-world study evaluating MYQORZO (aficamten) in symptomatic obstructive hypertrophic cardiomyopathy ($65.64, 0.00)

• 10:33 AM ET Sep 28, 2026
  

  StreetAccount M&A Summary: Week of 21-Sep

• 08:02 AM ET Sep 28, 2026
  

  Bayer announces U.S. FDA accepts sNDA and grants priority review to Lynkuet (elinzanetant) for new indication for treatment of moderate to severe vasomotor symptoms due to endocrine therapy related to breast cancer (€50.63, +0.61)

• 04:52 PM ET Sep 21, 2026
  

  Iambic Therapeutics, Inc. files for Nasdaq IPO of indeterminate amount - S-1